Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul 28:12:234.
doi: 10.1186/1477-7819-12-234.

Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study

Jia-jia Zhang, Wan-jun Sun, Zhong-xia Huang, Shi-lun Chen, Yu-ping Zhong, Ying Hu, Na An, Men Shen, Xin Li  1
Affiliations

Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study

Jia-jia Zhang et al. World J Surg Oncol. .

Abstract

Background: We intended to investigate the long-term clinical characteristics, responses to therapy and survival in patients with lightchain multiple myeloma (MM).

Methods: Ninety-six patients were enrolled into the study. There were 42 κ-chain MM patients and 54 λ-chain MM patients. All the patients werestage III in the Durie-Salmonstaging system. Among them, 66 patients received Velcade (bortezomib) treatment and the other 30 did not.

Results: The main symptoms of these patients included bone pain (77.1%), weakness and fatigue (12.5%), foamy urine (8.3%) and extramedullaryplasmocytomas (33.3%). The overall response rate (ORR) was 95.5% in patients treated with Velcade and 60%in the patients without. The median survival times were 23 months in patients treated with Velcade and 12 months in patients without. The median time of progression-free survival (PFS) was nine months in patients treated with Velcade and five months in patients without. The one-year PFS and two-year PFS were 37% and 25%, 27% and 9% for patients treated with Velcade, or without, respectively. The three-year overall survival (OS) and five-year OS were 33% and 24%, 28% and 9% for patients treated with Velcade, or without, respectively. There was no significance in OS between the two groups (P = 0.335). But there was significant difference in PFS between the two groups (P = 0.036).

Conclusions: Our long-term study demonstrated that patients with lightchain myeloma appeared to have more aggressive disease courses and poor outcomes, which could be improved by treatment with Velcade.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparing overall survival (OS) of the light chain multiple myeloma patients in the Velcade group and the group without Velcade (P = 0.335).
Figure 2
Figure 2
Comparing progression-free survival (PFS) of the light chain multiple myelomapatients in the Velcade group and the group without Velcade (P = 0.036).
See this image and copyright information in PMC

References

    1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860–1873. doi: 10.1056/NEJMra041875. - DOI - PubMed
    1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962–2972. doi: 10.1182/blood-2007-10-078022. - DOI - PMC - PubMed
    1. Mateos MV, San Miguel JF. Bortezomib in multiple myeloma. Best Pract Res ClinHaematol. 2007;20:701–715. doi: 10.1016/j.beha.2007.09.003. - DOI - PubMed
    1. McBride A, Ryan PY. Proteasome inhibitors in the treatment of multiple myeloma. Expert Rev Anticancer Ther. 2013;13:339–358. doi: 10.1586/era.13.9. - DOI - PubMed
    1. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147. doi: 10.7326/0003-4819-139-2-200307150-00013. - DOI - PubMed